Rapt Therapeutics (RAPT) Earnings Date, Estimates & Call Transcripts $10.58 -0.03 (-0.24%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Rapt Therapeutics Earnings Summary Rapt Therapeutics posted Q1 2025 earnings on May 8, 2025, reporting an EPS of -$0.64, which topped analysts' consensus estimates of -$2.48 by $1.84. With a trailing EPS of -$19.20, Rapt Therapeutics' earnings are expected to grow next year, from ($2.14) to ($1.35) per share. Upcoming Q2 Earnings DateAug. 6Before Market OpensEstimatedConsensus EPS (May. 8) -$2.48 Actual EPS (May. 8) -$0.64 Beat By $1.84 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)RAPT Upcoming EarningsRapt Therapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Powered by Get Rapt Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapt Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRAPT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Rapt Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$1.28-$1.28-$1.28Q2 20251-$0.66-$0.66-$0.66Q3 20251-$1.17-$1.17-$1.17Q4 20251-$0.97-$0.97-$0.97 Rapt Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/8/2025Q1 2025-$2.48-$0.64+$1.84-$0.08--3/6/2025Q4 2024-$3.60-$9.12 -$5.52-$1.14--11/12/2024--$4.48-$3.76+$0.72-$0.47--8/8/2024--$5.92-$5.68+$0.24-$0.71--5/9/2024Q1 2024-$6.24-$6.32 -$0.08-$0.79--3/7/2024Q4 2023-$6.80-$6.40+$0.40-$0.80--11/13/2023Q3 2023-$6.00-$6.56 -$0.56-$0.82--8/11/2023Q2 2023-$6.24-$5.28+$0.96-$0.66-- Rapt Therapeutics Earnings - Frequently Asked Questions When is Rapt Therapeutics' earnings date? Rapt Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on RAPT's earnings history. Did Rapt Therapeutics beat their earnings estimates last quarter? In the previous quarter, Rapt Therapeutics (NASDAQ:RAPT) reported ($0.64) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.48) by $1.84. Learn more on analysts' earnings estimate vs. RAPT's actual earnings. How much revenue does Rapt Therapeutics generate each year? Rapt Therapeutics (NASDAQ:RAPT) has a recorded annual revenue of $1.53 million. How much profit does Rapt Therapeutics generate each year? Rapt Therapeutics (NASDAQ:RAPT) has a recorded net income of -$129.87 million. RAPT has generated -$19.20 earnings per share over the last four quarters. What is Rapt Therapeutics' EPS forecast for next year? Rapt Therapeutics' earnings are expected to grow from ($2.14) per share to ($1.35) per share in the next year. More Earnings Resources from MarketBeat Related Companies Organogenesis Earnings Results Maze Therapeutics Earnings Results Tyra Biosciences Earnings Results Tilray Brands Earnings Results Taysha Gene Therapies Earnings Results Prime Medicine Earnings Results Oruka Therapeutics Earnings Results Bicycle Therapeutics Earnings Results Kura Oncology Earnings Results Bicara Therapeutics Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong This page (NASDAQ:RAPT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
